Sunshine Biopharma secures shareholder approval for Series D Warrant adjustments
SBFM•Sunshine Biopharma secured shareholder written consent for Series D Warrant provisions, including authorization to issue more than 20% of outstanding common shares at a deemed discount to the Nasdaq Minimum Price. A reverse split triggers a one-time warrant adjustment with a $5.50 minimum exercise price; the provisions are scheduled to take effect about 20 days after the information statement is mailed, around October 30.
1. Warrant provisions approved
Sunshine Biopharma secured shareholder written consent on October 13, 2026, for provisions covering its Series D Warrants. The consent authorizes issuance of more than 20% of outstanding common shares at a deemed discount to the Nasdaq Minimum Price.
2. Adjustment terms
The October 26 reverse split triggers a one-time Series D Warrant adjustment, with a minimum exercise price of $5.50. The board may also voluntarily reduce exercise prices, subject to Nasdaq rules. The provisions are scheduled to become effective 20 days after the information statement is mailed, expected around October 30.
